Liver cancer drug shows promise in Late-Stage trial
NCT ID NCT05117957
First seen Jan 03, 2026 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This study tested the drug sorafenib in 50 adults with advanced liver cancer that could not be removed by surgery and had worsened after at least one prior treatment. The goal was to see if sorafenib could slow cancer growth and to check its safety. Participants took sorafenib pills, and the study measured how long they lived without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center, Korea
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.